Replies to post #26916 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Funny how lol stated no company has ever been re-instated after revocation in history in earlier posts..Now, suddenly it is void and not void, and somehow magically different.. When all the facts that we presented are SEC rulings and facts..Not just typed words and heresay you understand...You are right...All Radient has to do is kill two birdies with one stone... Wolf..ahooooooooololoooo

[guardiangel]

DC Here is the last time Chalan would give me the outstanging shares 4,508,746,417 on July 18, 2013..From the 8-K on June 10,2013 it was 4,508,746,417 ...Do you see any difference? That was all that was issued..The remaining 491 million are for the reverse merger with Provista Diagnostics..imo Wolf


Chalan Harper
To
me
Jul 18, 2013

Good morning:



Currently à 4,508,746,417



Please contact me directly with any questions.



Thank you!



Chalan Harper

Executive Assistant/Client Services

Corporate Stock Transfer, Inc.

3200 Cherry Creek Drive South, Suite 430

Denver, CO 80209

Ph: 303-282-4800

Fax: [phone]

[e-mail]



http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113_radientpharm.htm

Section 8 – Other Events
Item 8.01 – Other Events

From an operational perspective, with appropriate capital, we can continue to sell and ship Onko-Sure® test kits to the following territories: Korea, Turkey, Taiwan, India, Vietnam, and the U.S. Despite significant financial hardship, we continue to maintain our offices and FDA approved manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants. We are also engaged in business discussions with other companies seeking to license or purchase Onko-Sure for various domestic and international territories, although we have not entered into any formal agreements at this time. We are hopeful that if we can complete a sufficient number of these licensing and sales agreements, we will have enough capital to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. These agreements may also allow us to restructure or convert to equity our existing notes payable in order to significantly reduce or eliminate a majority of the liabilities on our balance sheet. There can be no guarantee that any new licensing, purchase or restructuring transactions will be completed or that they will provide sufficient capital to carry out our plans.

As of June 10th 2013, we had approximately 4,508,746,417 shares of common stock issued and outstanding.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit No.

Description
10.1

Agreement with Uni Pharma Co., Ltd. dated June 6, 2013


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RADIENT PHARMACEUTICALS CORPORATION

By:

/s/ Douglas C. MacLellan
Name:

Douglas C. MacLellan
Title:

Chairman & CEO